In Friedreich ataxia (FRDA), early motor discoordination stems from dysfunctional sensory neurons in the spinal cord driven by epigenetic dysregulation, frataxin (FXN) deficiency, oxidative stress, and inflammation. Omaveloxolone, a nuclear factor erythroid 2-related factor-2 (NRF2) inducer, is the only treatment available. In various chronic disease models, sulforaphane (SF) can target NRF2 and the above processes. This study compared the effects of SF with omaveloxolone and dimethyl fumarate (DMF) in sensory neurons generated from FRDA patient-induced pluripotent stem cells and their isogenic control.
Results:
The successful generation of the FRDA and isogenic control sensory neurons was confirmed by the positive expression of β-III TUBULIN, BRN3A, ISLET1, PERIPHERIN, and tropomyosin receptor kinase C. In comparison with the isogenic control, FRDA sensory neurons displayed an aberrant gene expression profile alike to that reported in patients. None of the drugs affected the viability of the isogenic control sensory neurons. SF treatment improved the viability of FRDA sensory neurons by up to 61% versus the untreated control. DMF treatment showed a modest 35% increase, while omaveloxolone lacked an effect. SF-treated FRDA sensory neurons demonstrated increased reduced glutathione/oxidized glutathione ratio and expression of FXN and redox markers, and a reduced expression of selected epigenetic enzymes and inflammatory cytokines, at the respective gene and protein levels. DMF and omaveloxolone treatments only modulated some of these biomarkers.
Innovation:
We revealed the therapeutic potential of SF and how it performs in comparison with omaveloxolone and DMF, in a physiologically and genetically relevant in vitro FRDA model.
Conclusion:
SF offers a multipronged approach to alleviating the different cellular events underlying FRDA. Antioxid. Redox Signal. 43, 308–327.
Get full access to this article
View all access options for this article.
References
1.
AbetiR, BaccaroA, EsterasN, et al.Novel Nrf2-Inducer prevents mitochondrial defects and oxidative stress in friedreich’s ataxia models. Front Cell Neurosci, 2018; 12:188; doi: 10.3389/fncel.2018.00188
2.
AbetiR, UzunE, RenganathanI, et al.Targeting lipid peroxidation and mitochondrial imbalance in Friedreich’s ataxia. Pharmacol Res, 2015; 99:344–350; doi: 10.1016/j.phrs.2015.05.015
3.
Al-MahdawiS, PintoRM, IsmailO, et al.The Friedreich ataxia GAA repeat expansion mutation induces comparable epigenetic changes in human and transgenic mouse brain and heart tissues. Hum Mol Genet, 2008; 17(5):735–746; doi: 10.1093/hmg/ddm346
4.
Al-MahdawiS, PintoRM, VarshneyD, et al.GAA repeat expansion mutation mouse models of Friedreich ataxia exhibit oxidative stress leading to progressive neuronal and cardiac pathology. Genomics, 2006; 88(5):580–590; doi: 10.1016/j.ygeno.2006.06.015
5.
Ali KhanM, Kedhari SundaramM, HamzaA, et al.Sulforaphane reverses the expression of various tumor suppressor genes by targeting DNMT3B and HDAC1 in human cervical cancer cells. Evid Based Complement Alternat Med, 2015; 2015:412149; doi: 10.1155/2015/412149
6.
AlshawafAJ, ViventiS, QiuW, et al.Phenotypic and functional characterization of peripheral sensory neurons derived from human embryonic stem cells. Sci Rep, 2018; 8(1):603; doi: 10.1038/s41598-017-19093-0
7.
Ben-HamoR, Jacob BergerA, GavertN, et al.Predicting and affecting response to cancer therapy based on pathway-level biomarkers. Nat Commun, 2020; 11(1):3296; doi: 10.1038/s41467-020-17090-y
8.
BolottaA, PiniA, AbruzzoPM, et al.Effects of tocotrienol supplementation in Friedreich’s ataxia: A model of oxidative stress pathology. Exp Biol Med (Maywood), 2020; 245(3):201–212; doi: 10.1177/1535370219890873
9.
CaiH, ScottE, KholghiA, et al.Cancer chemoprevention: Evidence of a nonlinear dose response for the protective effects of resveratrol in humans and mice. Sci Transl Med, 2015; 7(298):298ra117; doi: 10.1126/scitranslmed.aaa7619
10.
CalabreseEJ, KozumboWJ. The phytoprotective agent sulforaphane prevents inflammatory degenerative diseases and age-related pathologies via Nrf2-mediated hormesis. Pharmacol Res, 2021; 163:105283; doi: 10.1016/j.phrs.2020.105283
11.
CalabreseV, CorneliusC, Dinkova-KostovaAT, et al.Cellular stress responses, the hormesis paradigm, and vitagenes: Novel targets for therapeutic intervention in neurodegenerative disorders. Antioxid Redox Signal, 2010; 13(11):1763–1811; doi: 10.1089/ars.2009.3074
12.
CalabreseV, MancusoC, CalvaniM, et al.Nitric oxide in the central nervous system: Neuroprotection versus neurotoxicity. Nat Rev Neurosci, 2007; 8(10):766–775; doi: 10.1038/nrn2214
13.
CampuzanoV, MonterminiL, MoltòMD, et al.Friedreich’s ataxia: Autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science, 1996; 271(5254):1423–1427; doi: 10.1126/science.271.5254.1423
14.
CarlettiB, PiemonteF. Friedreich’s Ataxia: A neuronal point of view on the oxidative stress hypothesis. Antioxidants (Basel), 2014; 3(3):592–603; doi: 10.3390/antiox3030592
15.
ChiangS, HuangMLH, ParkKC, et al.Antioxidant defense mechanisms and its dysfunctional regulation in the mitochondrial disease, Friedreich’s ataxia. Free Radic Biol Med, 2020; 159:177–188; doi: 10.1016/j.freeradbiomed.2020.07.019
16.
CodazziF, HuA, RaiM, et al.Friedreich ataxia-induced pluripotent stem cell-derived neurons show a cellular phenotype that is corrected by a benzamide HDAC inhibitor. Hum Mol Genet, 2016; 25(22):4847–4855; doi: 10.1093/hmg/ddw308
17.
DuP, ZhangW, CuiH, et al.Sulforaphane ameliorates the severity of psoriasis and SLE by modulating effector cells and reducing oxidative stress. Front Pharmacol, 2022; 13:805508; doi: 10.3389/fphar.2022.805508
18.
DulullNK, DiasDA, ThrimawithanaTR, et al.L-Sulforaphane confers protection against oxidative stress in an in vitro model of age-related macular degeneration. Curr Mol Pharmacol, 2018; 11(3):237–253; doi: 10.2174/1874467211666180125163009
19.
ErenE, TufekciKU, IsciKB, et al.Sulforaphane inhibits lipopolysaccharide-induced inflammation, cytotoxicity, oxidative stress, and mir-155 expression and switches to mox phenotype through activating extracellular signal-regulated kinase 1/2-nuclear factor erythroid 2-related factor 2/antioxidant response element pathway in murine microglial cells. Front Immunol, 2018; 9:36; doi: 10.3389/fimmu.2018.00036
20.
FolbergrovaJ, JesinaP, OtahalJ. Protective effect of sulforaphane on oxidative stress and mitochondrial dysfunction associated with status epilepticus in immature rats. Mol Neurobiol, 2023; 60(4):2024–2035; doi: 10.1007/s12035-022-03201-x
21.
FrohlichF, ReiserA, FinkL, et al.Multi-experiment nonlinear mixed effect modeling of single-cell translation kinetics after transfection. NPJ Syst Biol Appl, 2019; 5:1; doi: 10.1038/s41540-018-0079-7
22.
HayashiG, CortopassiG. Lymphoblast oxidative stress genes as potential biomarkers of disease severity and drug effect in friedreich’s ataxia. PLoS One, 2016; 11(4):e0153574; doi: 10.1371/journal.pone.0153574
23.
HickA, Wattenhofer-DonzeM, ChintawarS, et al.Neurons and cardiomyocytes derived from induced pluripotent stem cells as a model for mitochondrial defects in Friedreich’s ataxia. Dis Model Mech, 2013; 6(3):608–621; doi: 10.1242/dmm.010900
24.
HoughtonCA. Sulforaphane: Its “Coming of Age” as a clinically relevant nutraceutical in the prevention and treatment of chronic disease. Oxid Med Cell Longev, 2019; 2019:2716870; doi: 10.1155/2019/2716870
25.
HuL, CaoY, ChenH, et al.The Novel Nrf2 Activator omaveloxolone regulates microglia phenotype and ameliorates secondary brain injury after intracerebral hemorrhage in mice. Oxid Med Cell Longev, 2022; 2022:4564471; doi: 10.1155/2022/4564471
26.
HuXM, LiZX, LinRH, et al.Guidelines for regulated cell death assays: A systematic summary, A categorical comparison, a prospective. Front Cell Dev Biol, 2021; 9:634690; doi: 10.3389/fcell.2021.634690
27.
HulmeAJ, McArthurJR, MaksourS, et al.Molecular and functional characterization of neurogenin-2 induced human sensory neurons. Front Cell Neurosci, 2020; 14:600895; doi: 10.3389/fncel.2020.600895
28.
JasoliyaM, SaccaF, SahdeoS, et al.Dimethyl fumarate dosing in humans increases frataxin expression: A potential therapy for Friedreich’s Ataxia. PLoS One, 2019; 14(6):e0217776; doi: 10.1371/journal.pone.0217776
29.
JazwaA, RojoAI, InnamoratoNG, et al.Pharmacological targeting of the transcription factor Nrf2 at the basal ganglia provides disease modifying therapy for experimental parkinsonism. Antioxid Redox Signal, 2011; 14(12):2347–2360; doi: 10.1089/ars.2010.3731
30.
JiangLL, ZhouSJ, ZhangXM, et al.Sulforaphane suppresses in vitro and in vivo lung tumorigenesis through downregulation of HDAC activity. Biomed Pharmacother, 2016; 78:74–80; doi: 10.1016/j.biopha.2015.11.007
31.
JiangZ, QiG, LuW, et al.Omaveloxolone inhibits IL-1beta-induced chondrocyte apoptosis through the Nrf2/ARE and NF-kappaB signalling pathways in vitro and attenuates osteoarthritis in vivo. Front Pharmacol, 2022; 13:952950; doi: 10.3389/fphar.2022.952950
32.
KalininS, PolakPE, LinSX, et al.Dimethyl fumarate regulates histone deacetylase expression in astrocytes. J Neuroimmunol, 2013; 263(1–2):13–19; doi: 10.1016/j.jneuroim.2013.07.007
33.
Kaufman-SzymczykA, MajewskiG, Lubecka-PietruszewskaK, et al.The role of sulforaphane in epigenetic mechanisms, including interdependence between histone modification and DNA methylation. Int J Mol Sci, 2015; 16(12):29732–29743; doi: 10.3390/ijms161226195
34.
KobayashiGS, MussoCM, MoreiraDP, et al.Recapitulation of neural crest specification and EMT via induction from neural plate border-like cells. Stem Cell Reports, 2020; 15(3):776–788; doi: 10.1016/j.stemcr.2020.07.023
KuboE, ChhunchhaB, SinghP, et al.Sulforaphane reactivates cellular antioxidant defense by inducing Nrf2/ARE/Prdx6 activity during aging and oxidative stress. Sci Rep, 2017; 7(1):14130; doi: 10.1038/s41598-017-14520-8
37.
KwaFA, DulullNK, RoessnerU, et al.Lipidomics reveal the protective effects of a vegetable-derived isothiocyanate against retinal degeneration. F1000Res, 2019; 8:1067; doi: 10.1268/8/f1000research.19598.5
38.
KwaFAA, BuiBV, ThompsonBR, et al.Preclinical investigations on broccoli-derived sulforaphane for the treatment of ophthalmic disease. Drug Discov Today, 2023; 28(9):103718; doi: 10.1016/j.drudis.2023.103718
39.
La RosaP, PetrilloS, TurchiR, et al.The Nrf2 induction prevents ferroptosis in Friedreich’s ataxia. Redox Biol, 2021; 38:101791; doi: 10.1016/j.redox.2020.101791
40.
La RosaP, RussoM, D’AmicoJ, et al.Nrf2 induction re-establishes a proper neuronal differentiation program in Friedreich’s ataxia neural stem cells. Front Cell Neurosci, 2019; 13:356; doi: 10.3389/fncel.2019.00356
41.
LeeA. Omaveloxolone: First approval. Drugs, 2023; 83(8):725–729; doi: 10.1007/s40265-023-01874-9
42.
LiuY, HettingerCL, ZhangD, et al.Sulforaphane enhances proteasomal and autophagic activities in mice and is a potential therapeutic reagent for Huntington’s disease. J Neurochem, 2014; 129(3):539–547; doi: 10.1111/jnc.12647
43.
LuC, SchoenfeldR, ShanY, et al.Frataxin deficiency induces Schwann cell inflammation and death. Biochim Biophys Acta, 2009; 1792(11):1052–1061; doi: 10.1016/j.bbadis.2009.07.011
44.
LynchDR, ChinMP, DelatyckiMB, et al.Safety and efficacy of omaveloxolone in Friedreich ataxia (MOXIe Study). Ann Neurol, 2021; 89(2):212–225; doi: 10.1002/ana.25934
45.
LynchDR, FarmerJ, HauserL, et al.Safety, pharmacodynamics, and potential benefit of omaveloxolone in Friedreich ataxia. Ann Clin Transl Neurol, 2019; 6(1):15–26; doi: 10.1002/acn3.660
46.
LynchDR, PerlmanS, SchadtK. Omaveloxolone for the treatment of Friedreich ataxia: Clinical trial results and practical considerations. Expert Rev Neurother, 2024; 24(3):251–258; doi: 10.1080/14737175.2024.2310617
47.
MajkutewiczI. Dimethyl fumarate: A review of preclinical efficacy in models of neurodegenerative diseases. Eur J Pharmacol, 2022; 926:175025; doi: 10.1016/j.ejphar.2022.175025
48.
ManglaB, JavedS, SultanMH, et al.Sulforaphane: A review of its therapeutic potentials, advances in its nanodelivery, recent patents, and clinical trials. Phytother Res, 2021; 35(10):5440–5458; doi: 10.1002/ptr.7176
49.
MartinJH, DimmittS. The rationale of dose-response curves in selecting cancer drug dosing. Br J Clin Pharmacol, 2019; 85(10):2198–2204; doi: 10.1111/bcp.13979
50.
MayerC, Riera-PonsatiL, KauppinenS, et al.Targeting the NRF2 pathway for disease modification in neurodegenerative diseases: Mechanisms and therapeutic implications. Front Pharmacol, 2024; 15:1437939; doi: 10.3389/fphar.2024.1437939
51.
MazarakisN, SnibsonK, LicciardiPV, et al.The potential use of l-sulforaphane for the treatment of chronic inflammatory diseases: A review of the clinical evidence. Clin Nutr, 2020; 39(3):664–675; doi: 10.1016/j.clnu.2019.03.022
52.
MeeranSM, PatelSN, TollefsbolTO. Sulforaphane causes epigenetic repression of hTERT expression in human breast cancer cell lines. PLoS One, 2010; 5(7):e11457; doi: 10.1371/journal.pone.0011457
53.
MichoelT, ZhangJD. Causal inference in drug discovery and development. Drug Discov Today, 2023; 28(10):103737; doi: 10.1016/j.drudis.2023.103737
54.
MielletS, MaddockM, NapieralaJS, et al.Generation of genetically modified Friedreich’s ataxia induced pluripotent stem cell lines and isogenic control lines carrying an inducible neurogenin-2 expression cassette. Stem Cell Res, 2024a;79:103477; doi: 10.1016/j.scr.2024.103477
55.
MielletS, St Clair-GloverM, MaddockM, et al.Generation of a gene-edited H9 embryonic stem cell line carrying a DOX-inducible NGN2 expression cassette in the CLYBL locus. Stem Cell Res, 2024b;75:103312; doi: 10.1016/j.scr.2024.103312
56.
NachunD, GaoF, IsaacsC, et al.Peripheral blood gene expression reveals an inflammatory transcriptomic signature in Friedreich’s ataxia patients. Hum Mol Genet, 2018; 27(17):2965–2977; doi: 10.1093/hmg/ddy198
57.
PascaleCL, MartinezAN, CarrC, et al.Treatment with dimethyl fumarate reduces the formation and rupture of intracranial aneurysms: Role of Nrf2 activation. J Cereb Blood Flow Metab, 2020; 40(5):1077–1089; doi: 10.1177/0271678X19858888
58.
Pascual-AhuirA, Fita-TorróJ, ProftM. Capturing and understanding the dynamics and heterogeneity of gene expression in the living cell. Int J Mol Sci, 2020; 21(21); doi: 10.3390/ijms21218278
59.
PerlK, UshakovK, PozniakY, et al.Reduced changes in protein compared to mRNA levels across non-proliferating tissues. BMC Genomics, 2017; 18(1):305; doi: 10.1186/s12864-017-3683-9
60.
PetrilloS, D’AmicoJ, La RosaP, et al.Targeting NRF2 for the treatment of Friedreich’s ataxia: A comparison among drugs. Int J Mol Sci, 2019; 20(20); doi: 10.3390/ijms20205211
61.
PetrilloS, PiermariniE, PastoreA, et al.Nrf2-Inducers counteract neurodegeneration in frataxin-silenced motor neurons: Disclosing new therapeutic targets for Friedreich’s ataxia. Int J Mol Sci, 2017; 18(10); doi: 10.3390/ijms18102173
62.
PotashnikovaDM, SaidovaAA, TvorogovaAV, et al.Non-linear dose response of lymphocyte cell lines to microtubule inhibitors. Front Pharmacol, 2019; 10:436–436; doi: 10.3389/fphar.2019.00436
63.
ProbstBL, TrevinoI, McCauleyL, et al.RTA 408, A novel synthetic triterpenoid with broad anticancer and anti-inflammatory activity. PLoS One, 2015; 10(4):e0122942; doi: 10.1371/journal.pone.0122942
QuesadaMP, JonesJ, Rodriguez-LozanoFJ, et al.Novel aberrant genetic and epigenetic events in Friedreich’s ataxia. Exp Cell Res, 2015; 335(1):51–61; doi: 10.1016/j.yexcr.2015.04.013
66.
RameshV, KrishnanJ. A unified approach to dissecting biphasic responses in cell signaling. Elife, 2023; 13:e86520; doi: 10.7554/eLife.86520
67.
SahaS, ButtariB, PanieriE, et al.An Overview of Nrf2 Signaling Pathway and Its Role in Inflammation. Molecules, 2020; 25(22); doi: 10.3390/molecules25225474
68.
SalehHA, YousefMH, AbdelnaserA. The anti-inflammatory properties of phytochemicals and their effects on epigenetic mechanisms involved in TLR4/NF-kappaB-mediated inflammation. Front Immunol, 2021; 12:606069; doi: 10.3389/fimmu.2021.606069
69.
SamuelW, JaworskiC, PostnikovaOA, et al.Appropriately differentiated ARPE-19 cells regain phenotype and gene expression profiles similar to those of native RPE cells. Mol Vis, 2017; 23:60–89.
70.
Santin-MarquezR, Alarcon-AguilarA, Lopez-DiazguerreroNE, et al.Sulforaphane - role in aging and neurodegeneration. Geroscience, 2019; 41(5):655–670; doi: 10.1007/s11357-019-00061-7
71.
SchreiberAM, MisiorekJO, NapieralaJS, et al.Progress in understanding Friedreich’s ataxia using human induced pluripotent stem cells. Expert Opin Orphan Drugs, 2019; 7(2):81–90; doi: 10.1080/21678707.2019.1562334
72.
SilvaAM, BrownJM, BuckleVJ, et al.Expanded GAA repeats impair FXN gene expression and reposition the FXN locus to the nuclear lamina in single cells. Hum Mol Genet, 2015; 24(12):3457–3471; doi: 10.1093/hmg/ddv096
73.
Simões-PiresC, ZwickV, NurissoA, et al.HDAC6 as a target for neurodegenerative diseases: What makes it different from the other HDACs? Mol Neurodegener, 2013; 8(1):7–7; doi: 10.1186/1750-1326-8-7
74.
SinghS, AnshitaD, RavichandiranV. MCP-1: Function, regulation, and involvement in disease. Int Immunopharmacol, 2021; 101(Pt B):107598; doi: 10.1016/j.intimp.2021.107598
SunY, YangT, MaoL, et al.Sulforaphane protects against brain diseases: Roles of cytoprotective enzymes. Austin J Cerebrovasc Dis Stroke, 2017; 4(1); doi: 10.2642/0/austinjcerebrovascdisstroke.2017.1054
77.
TaguchiY, TurkiT. Novel method for the prediction of drug-drug Interaction based on gene expression profiles. Eur J Pharm Sci, 2021; 160:105742; doi: 10.1016/j.ejps.2021.105742
78.
TiberiJ, SegattoM, FiorenzaMT, et al.Apparent opportunities and hidden pitfalls: The conflicting results of restoring NRF2-regulated redox metabolism in Friedreich’s ataxia pre-clinical models and clinical trials. Biomedicines, 2023; 11(5); doi: 10.3390/biomedicines11051293
UddinMS, MamunAA, JakariaM, et al.Emerging promise of sulforaphane-mediated Nrf2 signaling cascade against neurological disorders. Sci Total Environ, 2020; 707:135624; doi: 10.1016/j.scitotenv.2019.135624
81.
VauzourD, BuonfiglioM, CoronaG, et al.Sulforaphane protects cortical neurons against 5-S-cysteinyl-dopamine-induced toxicity through the activation of ERK1/2, Nrf-2 and the upregulation of detoxification enzymes. Mol Nutr Food Res, 2010; 54(4):532–542; doi: 10.1002/mnfr.200900197
82.
VijayanV, WagenerF, ImmenschuhS. The macrophage heme-heme oxygenase-1 system and its role in inflammation. Biochem Pharmacol, 2018; 153:159–167; doi: 10.1016/j.bcp.2018.02.010
83.
ViventiS, FrausinS, HowdenSE, et al.In vivo survival and differentiation of Friedreich ataxia iPSC-derived sensory neurons transplanted in the adult dorsal root ganglia. Stem Cells Transl Med, 2021; 10(8):1157–1169; doi: 10.1002/sctm.20-0334
84.
VomundS, SchaferA, ParnhamMJ, et al.Nrf2, the master regulator of anti-oxidative responses. Int J Mol Sci, 2017; 18(12); doi: 10.3390/ijms18122772
85.
WheelerAM, EberhardCD, MosherEP, et al.Achieving a deeper understanding of drug metabolism and responses using single-cell technologies. Drug Metab Dispos, 2023; 51(3):350–359; doi: 10.1124/dmd.122.001043
86.
WuX, ZhaoJ, YuS, et al.Sulforaphane protects primary cultures of cortical neurons against injury induced by oxygen-glucose deprivation/reoxygenation via antiapoptosis. Neurosci Bull, 2012; 28(5):509–516; doi: 10.1007/s12264-012-1273-z
87.
XuC, SoragniE, ChouCJ, et al.Chemical probes identify a role for histone deacetylase 3 in Friedreich’s ataxia gene silencing. Chem Biol, 2009; 16(9):980–989; doi: 10.1016/j.chembiol.2009.07.010
88.
YanezM, JhanjiM, MurphyK, et al.Nicotinamide augments the anti-inflammatory properties of Resveratrol through PARP1 Activation. Sci Rep, 2019; 9(1):10219; doi: 10.1038/s41598-019-46678-8
89.
YangF, WangF, LiuY, et al.Sulforaphane induces autophagy by inhibition of HDAC6-mediated PTEN activation in triple negative breast cancer cells. Life Sci, 2018a;213:149–157; doi: 10.1016/j.lfs.2018.10.034
90.
YangW, ThompsonB, KwaFAA. Molecular approaches for the treatment and prevention of Friedreich’s ataxia. Drug Discov Today, 2022; 27(3):866–880; doi: 10.1016/j.drudis.2021.11.003
91.
YangY, LuoL, CaiX, et al.Nrf2 inhibits oxaliplatin-induced peripheral neuropathy via protection of mitochondrial function. Free Radic Biol Med, 2018b;120:13–24; doi: 10.1016/j.freeradbiomed.2018.03.007
92.
ZhangJ, ZhangR, ZhanZ, et al.beneficial effects of sulforaphane treatment in Alzheimer’s disease may be mediated through reduced hdaC1/3 and increased P75NTR expression. Front Aging Neurosci, 2017; 9:121; doi: 10.3389/fnagi.2017.00121
93.
ZhaoF, ZhangJ, ChangN. Epigenetic modification of Nrf2 by sulforaphane increases the antioxidative and anti-inflammatory capacity in a cellular model of Alzheimer’s disease. Eur J Pharmacol, 2018; 824:1–10; doi: 10.1016/j.ejphar.2018.01.046
94.
ZighanM, ArkadirD, DouievL, et al.Variable effects of omaveloxolone (RTA408) on primary fibroblasts with mitochondrial defects. Front Mol Biosci, 2022; 9:890653; doi: 10.3389/fmolb.2022.890653
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
